Anti-tissue factor monoclonal antibody

Patent metadata

Field	Value
Publication number	US-9920133-B2
Application number	US-201515111875-A
Country	US
Kind code	B2
Filing date	Feb 3, 2015
Priority date	Feb 3, 2014
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.

First claim

The invention claimed is:

1. A monoclonal antibody or biologically active fragment thereof, which binds to tissue factor, selected from the group consisting of:
an anti-human tissue factor monoclonal antibody or biologically active fragment thereof including a heavy chain variable region having complementarity determining regions 1, 2, and 3 containing the amino acid sequences set forth in SEQ ID NOS: 3, 4, and 5, respectively, and a light chain variable region having complementarity determining regions 1, 2, and 3 containing the amino acid sequences set forth in represented by SEQ ID NOS: 6, 7, and 8, respectively; and
an anti-human tissue factor monoclonal antibody or biologically active fragment thereof including a heavy chain variable region having complementarity determining regions 1, 2, and 3 containing the amino acid sequences set forth in represented by SEQ ID NOS: 11, 12, and 13, respectively, and a light chain variable region having complementarity determining regions 1, 2, and 3 containing the amino acid sequences set forth in represented by SEQ ID NOS: 14, 15, and 16, respectively.

2. The monoclonal antibody according to claim 1 , selected from the group consisting of:
an anti-human tissue factor monoclonal antibody or biologically active fragment thereof including a heavy chain variable region containing the amino acid sequence set forth in SEQ ID NO: 9 or an amino acid sequence which is 90% or more identical to the amino acid sequence set forth in SEQ ID NO: 9, and a light chain variable region containing the amino acid sequence set forth in SEQ ID NO: 10 or an amino acid sequence which is 90% or more identical to the amino acid sequence set forth in SEQ ID NO: 10; and
an anti-human tissue factor monoclonal antibody or biologically active fragment thereof including a heavy chain variable region containing the amino acid sequence set forth in SEQ ID NO: 17 or an amino acid sequence which is 90% or more identical to the amino acid sequence set forth in SEQ ID NO: 17, and a light chain variable region containing the amino acid sequence set forth in SEQ ID NO: 18 or an amino acid sequence which is 90% or more identical to the amino acid sequence set forth in SEQ ID NO: 18.

3. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody is a human chimeric antibody or a humanized antibody.

4. A pharmaceutical composition, comprising:
the monoclonal antibody or biologically active fragment thereof of claim 1 as a target-binding factor; and
a drug.

5. A composition for drug delivery, comprising the monoclonal antibody or biologically active fragment thereof of claim 1 as a target-binding factor.

6. A pharmaceutical composition, comprising:
the monoclonal antibody or biologically active fragment thereof of claim 2 as a target-binding factor; and
a drug.

7. A composition for drug delivery, comprising the monoclonal antibody or biologically active fragment thereof of claim 2 as a target-binding factor.

8. An isolated nucleic acid sequence encoding an antibody or biologically active fragment thereof comprising the heavy chain CDR sequences and light chain CDR sequences according to claim 1 .

9. An isolated nucleic acid sequence encoding an antibody or antigen-binding fragment thereof according to claim 2 .

10. An expression vector comprising the nucleic acid sequence of claim 8 .

11. An expression vector comprising the nucleic acid sequence of claim 9 .

12. A host cell comprising the vector of claim 10 .

13. A host cell comprising the vector of claim 11 .

14. A method for treating cancer, inflammation, or thrombosis, comprising administering to a patient in need thereof the monoclonal antibody or biologically active fragment thereof according to claim 1 bound to a drug effective for treating cancer, inflammation, or thrombosis.

15. A method for treating cancer, inflammation, or thrombosis, comprising administering to a patient in need thereof the monoclonal antibody or biologically active fragment thereof according to claim 2 bound to a drug effective for treating cancer, inflammation, or thrombosis.

16. A method for treating cancer, inflammation, or thrombosis, comprising administering to a patient in need thereof the pharmaceutical composition according to claim wherein the drug is effective for treating cancer, inflammation, or thrombosis and wherein the drug is bound to the monoclonal antibody or biologically active fragment thereof.

17. A method for treating cancer, inflammation, or thrombosis, comprising administering to a patient in need thereof the pharmaceutical composition according to claim 4 , wherein the drug is effective for treating cancer, inflammation, or thrombosis and wherein the drug is bound to the monoclonal antibody or biologically active fragment thereof.

18. The method for treating cancer, inflammation, or thrombosis according to claim 14 , wherein the monoclonal antibody or biologically active fragment thereof binds to tissue factor at a dissociation constant (KD) of 2×10 −10 M or less.

19. The monoclonal antibody or biologically active fragment thereof according to claim 1 , wherein the monoclonal antibody or biologically active fragment thereof binds to tissue factor at a dissociation constant (KD) of 2×10 −10 M or less.

Assignees

• Nat Cancer Ct
• Univ Tokyo
• Riken
• Nanocarrier Co Ltd

Inventors

• Matsumura Yasuhiro
• Yasunaga Masahiro
• Koga Yoshikatsu
• Yamamoto Yoshiyuki
• Sato Ryuta
• Tsumura Ryo
• Kataoka Kazunori
• Nishiyama Nobuhiro
• Miura Yutaka
• Manabe Shino
• Kato Yasuki

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• C07K16/36 Primary

  against blood coagulation factors · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title